These findings highlight the importance of dose effects, even with the same anticancer agents, and reveal that HDAC inhibition by TSA affects multiple pathways that culminate in B-CLL sensitivity to TRAIL-mediated apoptosis. This evidence concerns the gene TNFSF10 and B-cell chronic lymphocytic leukemia.